Sophisticated Investor, page-13

Words or phrases such as 'first in class' or "world first' have so far failed to invigorate large scale interest in this company.

Potential investors have arguably been baulked by negatives such as 'early days' or 'pre-clinical' or those who may have done some research - 'failed phase 3 trial'.

Although yet to be either demonstrated in a human trial or even mentioned outright, the Cantrixil news this week has thrown three new words into the mix ... 'proof of concept'. These would have to be among the most sought after words in the biotech sector.

If we get the same result in women with refractory ovarian cancer, then we become pretty close to adding 'holy grail' to the list.

Let the scramble begin.